SERPINE-1 gene polymorphism in patients with cardiovascular diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Currently, the issues of recurrent course of cardiovascular diseases are given great importance. Today, there is a search for more and more new factors and causes, including genetic ones, that contribute to the increase in the incidence of circulatory system diseases. The study of polymorphic variants of hemostasis system genes made it possible to study the molecular mechanisms underlying the causes of cardiovascular complications. Polymorphism of the SERPINE-1 gene, encoding plasminogen activator inhibitor-1, is associated with the occurrence of cardiovascular diseases. This literature review examines the influence of SERPINE-1 gene polymorphism and the concentration of the plasminogen activator inhibitor-1 it encodes on the development and severity of circulatory system diseases; as well as the role of plasminogen activator inhibitor-1 as one of the indicators reflecting the antifibrinolytic potential of the blood. Taking into account the opinion of most authors, we can conclude that the polymorphism of the SERPINE-1 gene and its homozygous variant 4G/4G, due to which the synthesis of plasminogen activator inhibitor-1 is increased, is an unfavorable predictor of many pathological processes. However, most of the data have been obtained on the association of the SERPINE-1 gene polymorphism with cardiovascular diseases, where, according to most authors, the 4G/4G genotype is a prognostically negative variant. However, a number of researchers believe that the heterozygous 5G/4G variant is likely associated with the occurrence of cerebral ischemia. The inconsistency of the data obtained, of course, requires further study of the characteristics of the SERPINE-1 gene polymorphism in various pathological conditions, which is an important prerequisite for understanding the mechanisms of a number of diseases. To prepare the review, a literature search method in PubMed databases for the period 2013–2023 was used.

About the authors

Aigul F. Usmanova

Kazan State Medical University

Author for correspondence.
Email: Y.Aigul5543823@yandex.ru
ORCID iD: 0000-0001-8850-1843

Postgrad. Stud., Hospital Therapy Department

Russian Federation, Kazan

Svetlana D. Mayanskaya

Kazan State Medical University

Email: Smayanskaya@mail.ru
ORCID iD: 0000-0001-6701-5395

M.D., D. Sci. (Med.), Prof., Hospital Therapy Depart.

Russian Federation, Kazan

Olga A. Kravtsova

Kazan (Volga Region) Federal University

Email: okravz@yandex.ru
ORCID iD: 0000-0002-4227-008X

Cand. Sci. (Biol.), Assoc. Prof., Depart. of Biochemistry, Biotechnology and Pharmacology

Russian Federation, Kazan

References

  1. Rosstat data as of June 22, 2019. https://www.gsk.ru (access date: 05.10.2023). (In Russ.)
  2. Piepoli MF, Corrà U, Benzer C, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AO, Schmid JP. Secondary prevention through cardiac rehabilitation: From knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010;17(1):1–17. doi: 10.1097/HJR.0b013e3283313592.
  3. Plekhova NG, Brodskaya TA, Nevzorova VA, Repina NI, Eliseeva VS. Single nucleotide substitution in the matrix metalloproteinase 9 gene hypertensive individuals of European and South Asian ethnicity in the Far Eastern Federal District. Cardiovascular therapy and prevention. 2022;21(1):2874. (In Russ.) doi: 10.15829/1728-8800-2022-2874.
  4. Abboud N, Ghazouani L, Saidi S, Khlifa SB. Association of PAI-1 4G/5G and –844G/A gene polymorphisms and changes in PAI-1/TPA levels in myocardial infarction. A casecontrol study. Archives of Cardiovascular Diseases. 2010;14(1):23–27. doi: 10.1016/S1875-2136(09)72149-7.
  5. El-Aziz TAA, Rezk NA. Relation of PAI-1 and TPA genes polymorphisms to acute myocardial infarction and its outcomes in Egyptian patients. Cell Biochem Biophys. 2015;71(1):227–334. doi: 10.1007/s12013-014-0188-x.
  6. Kugaevskaya EV, Gureeva TA, Timoshenko OS, Solovyeva NI. Urokinase-type plasminogen activator system in norm and in life-threatening processes. General reanimatology. 2018;6:61–79. (In Russ.) doi: 10.15360/1813-9779-2018-6-61-79.
  7. Dedov II, Mel’nichenko GA, Butrova SA. Adipose tissue as an endocrine organ. Ozhirenie i metabolizm. 2006;3(1):6–13. (In Russ.) EDN: KZWGBZ.
  8. Burkova TV, Goncharova IA. Genetic factors influencing the effectiveness and safety of long-term anticoagulant therapy. Cardiovascular Therapy and Prevention. 2013;12(3):89–94. (In Russ.) doi: 10.15829/1728-8800-2013-3-89-94.
  9. Lopukhov SV, Filippov EV. Association of combinations of single-nucleotide polymorphisms in noncommunicable diseases and adverse outcomes in women with premature ovarian insufficiency. Russkiy meditsinskiy zhurnal. 2022;(8):55–60. (In Russ.) EDN: RDUFKA.
  10. Сharnaia MA, Dementeva II. Hemostasis system in the abdominal aorta aneurysms. Kardiologiya i serdechno-sosudistaya khirurgiya. 2017;10(4):4–7. (In Russ.) doi: 10.17116/kardio20171044-7.
  11. Parry DJ, Al-Barjas HS, Chappell L, Ariens RA, Scott DJ. Haemostatic and fibrinolytic factors in men with a small abdominal aortic aneurysm. Br J Surg. 2009;96(8):870–877. doi: 10.1016/j.jvs.2010.02.279.
  12. Folsom AR, Alonso A, Lutsey PL, Missov E. Circulating biomarkers and abdominal aortic aneurysm incidence: The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2015;132(7):578–585. DOI: 10.1161.115.016537.
  13. Kremers BMM, Posma JN, Heitmeier S, Glunz J, Cate HT, Pallares Robles A, Daemen JHC, Cate-Hoek AJT, Mees BME, Spronk HMH. Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease. Sci Rep. 2022;12:7–11. doi: 10.1038/s41598-022-23260-3.
  14. Chang ML, Lin YS, Pao LH, Huang HC, Chiu CT. Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance. Sci Rep. 2017;50–69. doi: 10.1038/srep42503.
  15. Altahli R, Pechlivani N, Ajjan RA. PAI-1 in diabetes: Pathophysiology and role as a therapeutic target. Int J Mol Sci. 2021;22(6):1–15. doi: 10.3390/ijms22063170.
  16. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283(2):209–220. doi: 10.1152/ajprenal.00032.2002.
  17. Roka-Moya YM, Bilous VL, Zhernossekov DD, Rybachuk VN, Grinenko TV. Development and validation of the method for measuring plasminogen activator inhibitor-1 activity in blood plasmas. Materials of the V International Scientific and Practical Conference. Council of Young Scientists and Specialists under the Head of the Republic of North Ossetia-Alania. 2014. р. 176–179. (In Russ.)
  18. Wejkum L, Chmielewska J. A new adaptation of Coatest® PAI for measurements of low inhibitor concentrations in plasma. Fibrinolysis. 1990;4:130–131. doi: 10.1016/0268-9499(90)90387-Y.
  19. Wayne L, Chandler MD. Laboratory techniques in fibrinolysis testing. In: Transfusion medicine and hemostasis. Third Edition. Elsevier; 2019. р. 865–868. doi: 10.1016/B978-0-12-813726-0.00146-X.
  20. Deng G, Scott A, Hu G, Czekay RP, Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol. 2001;189(1):23–33. doi: 10.1002/jcp.1133.
  21. Madach K, Aladzsity I, Szilagyi A, Fust F, Gal J, Penzes I, Prohaszka Z. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: Prospective, observational, genetic study. Crit Care. 2010;14(2):79–82. doi: 10.1186/cc8992.
  22. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995;86(11):4007–4024. doi: 10.1182/blood.V86.11.4007.bloodjournal86114007.
  23. Labaratornaya diagnostika narusheniy gemostaza. (Laboratory diagnostics of hemostasis disorders.) VV Dolgov, PV Svirin eds. National guidelines. Tver: Triada; 2005. 227 p. (In Russ.)
  24. Placencio VR, DeClerck YA. Plasminogen activator inhibitor-1 in cancer: Rationale and insight for future therapeutic testing. Cancer Res. 2015;75(15):2969–2974. doi: 10.1158/0008-5472.CAN-15-0876.
  25. Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A. Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE. Transl Oncol. 2015;8:273–278. doi: 10.1016/j.tranon.2015.05.002.
  26. Zhang X, Cai X, Pan J. Correlation between PAI-1 Gene 4G/5G polymorphism and the risk of thrombosis in Ph chromosome-negative myeloproliferative neoplasms. Clin Appl Thromb Hemost. 2020;26:1–7. doi: 10.1177/1076029620935207.
  27. Zhai J, Li Z, Zhou Y, Yang X. The role of plasminogen activator inhibitor-1 in gynecological and obstetrical diseases: An update review. J Reprod Immunol. 2022;150:10–18. doi: 10.1016/j.jri.2022.103490.
  28. Ye Y, Vattai A, Zhang X, Zhu J, Thaler CJ, Mahner S, Jeschke U, von Schönfeldt V. Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases. Int J Mol Sci. 2017;18(8):36–51. doi: 10.3390/ijms18081651.
  29. Alexandrova NV, Donnikov AE. Obstetric complications in high-risk pregnancy. Forecasting capabilities. Bulletin of Peoples' Friendship University of Russia. Series: Medical. 2012;(5):104–108. (In Russ.) EDN: VBNIUB.
  30. Nikolaeva MG, Serdjuk GV, Gorbacheva TI, Yavorskaya SD, Momot AP. Relationship between preeclampsia and SERPINE1 (PAI-1-675 G4/G5) gene polymorphism. Systematic review. A meta-analysis. Russian Journal of Human Reproduction. 2016;22(4):115-122. (In Russ.) doi: 10.17116/repro2016224115-122.
  31. Godtfredsen AC, Sidelmann JJ, Dolleris BB, Jørgensen JS, Johansen EKJ, Pedersen MFB, Palarasah Y, Gram JB. Fibrinolytic changes in women with preeclampsia. Clin Appl Thromb Hemost. 2022;28(9):1–11. doi: 10.1177/10760296221126172.
  32. Tosun O, Erdemoğlu M, Çöğendez E. Investigation of plasminogen activator inhibitor-1 4G/5G gen polymorphism in Turkish preeclamptic patients. Zeynep Kamil Med J. 2021;52(2):61–66. doi: 10.14744/zkmj.2021.87609.
  33. Gerhardt A, Goecke TW, Beckmann MW, Wagner KJ, Tutschek B, Willers R, Bender HG, Scharf RE, Zotz RB. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost. 2005;3(4):686–691. doi: 10.1111/j.1538-7836.2005.01226.x.
  34. Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL. Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 2005;314(2):710–716. doi: 10.1124/jpet.105.084129.
  35. Kellici TF, Pilka ES, Bodkin MJ. Therapeutic potential of targeting plasminogen activator inhibitor-1 in COVID-19. Trends Pharmacol Sci. 2021;42(6):431–433. doi: 10.1016/j.tips.2021.03.006.
  36. Kwaan HC, Lindholm PF. The central role of fibrinolytic response in COVID-19 — A hematologist's perspective. Int J Mol Sci. 2021;22(3):1–16. doi: 10.3390/ijms22031283.
  37. Sillen M, Declerck PJ. Targeting PAI-1 in cardiovascular disease: Structural insights into PAI-1 functionality and inhibition. Front Cardiovasc Med. 2020;7(22):1–24. doi: 10.3389/fcvm.2020.622473.
  38. Ploplis VA. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets. 2011;12(12):1782–1789. doi: 10.2174/138945011797635803.
  39. Liang Z, Jiang W, Ouyang M, Yang K. PAI-1 4G/5G polymorphism and coronary artery disease risk: A meta-analysis. Int J Clin Exp Med. 2015;8(2):2097–2107. PMID: 25932140.
  40. Osmak GJ, Sidko AR, Kiselev IS, Favorova OO. Age-dependent approach to searching for genetic variants associated with myocardial infarction. Mol Biol (Mosk). 2020;54(4):699–704. (In Russ.) doi: 10.31857/S0026898420040138.
  41. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36(8):1661–1665. doi: 10.1161/01.STR.0000174485.10277.24.
  42. Tang J, Zhu W, Mei X, Zhang Z. Plasminogen activator inhibitor-1: A risk factor for deep vein thrombosis after total hip arthroplasty. J Orthop Surg Res. 2018;13(1):1–8. doi: 10.1186/s13018-018-0716-2.
  43. Huang G, Wang P, Li T, Deng X. Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta-analysis. Clin Cardiol. 2019;42(12):1232–1238. doi: 10.1002/clc.23282.
  44. Liu Y, Cheng J, Guo X, Mo J, Gao B, Zhou H, Wu Y, Li Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects. Gene. 2018;673:167–173. doi: 10.1016/j.gene.2018.06.040.
  45. Shamma DMR, Sabbagh AS, Taher AT, Zaatari GS, Mahfouz RAR. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population. Mol Biol Rep. 2008;35(3):453–457. doi: 10.1007/s11033-007-9106-2.
  46. Zhang ZA, Ji XW, Guan LX. Association of PAI-1 gene polymorphism with prognosis of coronary artery disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008;25(2):233–235. PMID: 18393255.
  47. Wiley K, Sanina C. Systemic thromboembolism in a patient with pfo and SERPINE-1 gene homozygous 4G/4G variant. J Am Coll Cardiol. 2021;77(18):64–69. doi: 10.1016/S0735-1097(21)03335-0.
  48. Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, Goracy I, Chetstowski K, Wesotowska T. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis. 2004;14(5):259–269. doi: 10.1016/s0939-4753(04)80053-x.
  49. Jacobs A, Schutte AE, Ricci C, Pieters M. Plasminogen activator inhibitor-1 activity and the 4G/5G polymorphism are prospectively associated with blood pressure and hypertension status. J Hypertens. 2019;37(12):2361–2370. doi: 10.1097/HJH.0000000000002204.
  50. Lapić I, Antolic MR, Horvat I, Premužić V, Palić J, Rogić D, Zadro R. Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: A pilot study. J Med Virol. 2022;94(8):3669–3675. doi: 10.1002/jmv.27774.
  51. Hendrix P, Foreman PM, Harrigan MR, Fisher WR 3rd, Vyas AV, Lipsky RH, Lin M, Walters BC, Tubbs RS, Shoja MM, Pittet JF, Mathru M, Griessenauer CJ. Association of plasminogen activator inhibitor 1 (SERPINE1 gene) polymorphisms and aneurysmal subarachnoid hemorrhage. World Neurosurg. 2017;105:672–677. doi: 10.1016/j.wneu.2017.05.175.
  52. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998;79(5):975–979.
  53. Kucukarabaci B, Gunes HV, Ozdemir G, Cosan D, Ozbabalik D, Dikmen M, Degirmenci I. Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke. Genet Test. 2008;12(3)443–451. doi: 10.1089/gte.2008.0025.
  54. Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L, Patrassi GM, Girolami A. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Thromb Hemost. 2003;9(4):299–307. doi: 10.1177/107602960300900405.
  55. Kopytek M, Ząbczyk M, Mazur P, Undas A, Natorska J. PAI-1 overexpression in valvular interstitial cells contributes to hypofibrinolysis in aortic stenosis. Cells. 2023;12(10):1402–1405. doi: 10.3390/cells12101402.
  56. Song C, Burgess S, Eicher J, O'Donnell CJ, Johnson AD. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc. 2017;6(6):1–24. doi: 10.1161/JAHA.116.004918.
  57. Ozkan B, Cagliyan CE, Elbasan Z, Uysal OK, Kalkan GY, Bozkurt M, Tekin K, Bozdogan ST, Ozalp O, Duran M, Sahin DY, Cayli M. PAI-1 4G/5G gene polymorphism is associated with angiographic patency in ST-elevation myocardial infarction patients treated with thrombolytic therapy. Coron Artery Dis. 2012;23(6):400–403. doi: 10.1097/MCA.0b013e3283576a77.
  58. Nikolopoulos GK, Bagos PG, Tsangaris I, Tsiara CG, Kopterides P, Vaiopoulos A, Kapsimali V, Bonovas S, Tsantes AE. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: A Mendelian randomization meta-analysis. Clin Chem Lab Med. 2014;52(7):937–950. doi: 10.1515/cclm-2013-1124.
  59. Cagliyan CE, Yuregir OO, Balli M, Tekin K, Akilli RE, Bozdogan ST, Turkmen S, Deniz A, Baykan OA, Aslan H, Cayli M. Plasminogen activator inhibitor-1 5G/5G genotype is associated with early spontaneous recanalization of the infarct-related artery in patients presenting with acute ST-elevation myocardial infarction. Coron Artery Dis. 2013;24(3):196–200. doi: 10.1097/MCA.0b013e32835d7633.
  60. Rallidis LS, Gialeraki A, Merkouri E, Liakos G, Dagres N, Sionis D, Travlou A, Lekakis J, Kremastinos DT. Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction. J Thromb Thrombolysis. 2010;29(4):497–502. doi: 10.1007/s11239-009-0398-z.
  61. Flevaris P, Khan SS, Eren M, Schuldt AJT, Shah SJ, Lee DC, Gupta S, Shapiro AD, Burridge PW, Ghosh AK, Vaughan DE. Plasminogen activator inhibitor type I controls cardiomyocyte transforming growth factor-β and cardiac fibrosis. Circulation. 2017;136(7):664–679. doi: 10.1161/CIRCULATIONAHA.117.028145.
  62. Zhang Q, Jin Y, Li X, Peng XQ, Peng N, Song JF, Xu M. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism — a meta-analysis and systematic review. Vasa. 2020;49(2):141–146. doi: 10.1024/0301-1526/a000839.
  63. Wang Z, Kong L, Luo G, Zhang H, Sun F, Liang W, Wu W, Guo Z, Zhang H, Dou Y. Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism. Thromb J. 2022;20(1):68–72. doi: 10.1186/s12959-022-00430-x.
  64. Prabhudesai A, Shetty S, Ghosh K, Kulkarni B. Investigation of plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study. Eur J Haematol. 2017;99(3):249–256. doi: 10.1111/ejh.12912.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2024 Eco-Vector

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».